Drug intelligence / Profile preview

hydralazine + hydrochlorothiazide + reserpine

Development stage: Discontinued
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

A combination medication containing hydralazine, hydrochlorothiazide, and reserpine used to treat hypertension (high blood pressure). The medication works through multiple mechanisms: hydralazine acts as a vasodilator relaxing blood vessels, hydrochlorothiazide functions as a diuretic causing the kidneys to eliminate excess water and salt, and reserpine depletes catecholamines from peripheral sympathetic nerve endings affecting heart rate and vascular resistance.

Brand names: Ser-Ap-EsHydrap-ESUnipresCam-Ap-EsSer-A-GenHydroserpine PlusMarpresSerathideSerpazideSerpexTri-HydroserpineUni Serp

Targets

SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)VMAT2 (Vesicular monoamine transporter 2)

Beyond the preview

Go deeper on hydralazine + hydrochlorothiazide + reserpine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydralazine + hydrochlorothiazide + reserpine.

Explore the full profile